Healthcare -
Biotechnology - NASDAQ - US
$ 0.1001
12.1 %
$ 1.5 M
Market Cap
-0.03
P/E
1. INTRINSIC VALUE
Balance Sheet
Jasper Therapeutics, Inc.
| Current Assets | 75.8 M |
| Cash & Short-Term Investments | 71.6 M |
| Receivables | 0 |
| Other Current Assets | 4.17 M |
| Non-Current Assets | 4.09 M |
| Long-Term Investments | 0 |
| PP&E | 2.85 M |
| Other Non-Current Assets | 1.24 M |
| Current Liabilities | 15.2 M |
| Accounts Payable | 4.03 M |
| Short-Term Debt | 1.09 M |
| Other Current Liabilities | 10.1 M |
| Non-Current Liabilities | 2.99 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 2.99 M |
EFFICIENCY
Earnings Waterfall
Jasper Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 76.2 M |
| Operating Income | -76.2 M |
| Other Expenses | -4.97 M |
| Net Income | -71.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Jasper Therapeutics, Inc.
| Net Income | -71.3 M |
| Depreciation & Amortization | 1.37 M |
| Capital Expenditures | -552 K |
| Stock-Based Compensation | 6.62 M |
| Change in Working Capital | 173 K |
| Others | 797 K |
| Free Cash Flow | -63.2 M |
Wall Street Analysts Price Targets
Jasper Therapeutics, Inc.
JSPRW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
JSPRW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Jasper Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile
Summary
Jasper Therapeutics, Inc. JSPRW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.5 M
Dividend Yield
0.00%
Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Contact
2200 Bridge Pkwy, Redwood City, DE, 94065
https://www.jaspertherapeutics.com/
IPO
Date
None
Employees
64
Officers
Mr. Matthew Ford
Senior Vice President of Human Resources
Ms. Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality
Mr. David Ku M.D.
Vice President of Corporate Development, Portfolio Strategy & Management
Mr. Herbert C. Cross CPA
Chief Financial Officer & Corporate Secretary
Mr. Ronald A. Martell
President, Chief Executive Officer & Director
Dr. Judith Anne Shizuru M.D., Ph.D.
Co-Founder, Member of Scientific Advisory Board & Director
Dr. Wendy Pang M.D., Ph.D.
Senior Vice President of Research & Translational Medicine
Mr. Jeetinder Singh Mahal M.B.A.
Chief Operating Officer
Dr. Luca Di Noto Ph.D.
Senior Vice President of Technical Operations
Dr. Edwin Jonathan Tucker M.D.
Chief Medical Officer